Daraprim Side Effects
Generic name: pyrimethamine
Note: This document contains side effect information about pyrimethamine. Some of the dosage forms listed on this page may not apply to the brand name Daraprim.
Some side effects of Daraprim may not be reported. Always consult your doctor or healthcare specialist for medical advice. You may also report side effects to the FDA.
For the Consumer
Applies to pyrimethamine: oral tablet
Along with its needed effects, pyrimethamine (the active ingredient contained in Daraprim) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.
Check with your doctor immediately if any of the following side effects occur while taking pyrimethamine:Less common
- Black, tarry stools
- blood in urine or stools
- cough or hoarseness
- fever or chills
- irritation or soreness of tongue
- lower back or side pain
- painful or difficult urination
- pinpoint red spots on skin
- unusual bleeding or bruising
- Bleeding or crusting sores on lips
- chest pain or discomfort
- muscle cramps or pain
- redness, blistering, peeling, or loosening of skin
- skin rash
- sores, ulcers, and/or white spots in mouth
- sore throat
- unusual tiredness or weakness
- Blood in urine
- difficulty swallowing
- fainting spells
- fast, slow, or irregular heartbeat
- joint or muscle pain
- pale skin
- pounding or rapid pulse
- puffiness or swelling of the eyelids or around the eyes, face, lips or tongue
- rapid breathing
- red, irritated eyes
- red skin lesions, often with a purple center
- shortness of breath
- swollen glands
- tightness in chest
- unexplained bleeding or bruising
- Abdominal or stomach pain
- convulsions (seizures)
- increased excitability
- vomiting (severe and continuing)
Some side effects of pyrimethamine may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects. Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:Less common
- loss of appetite
For Healthcare Professionals
Applies to pyrimethamine: compounding powder, oral tablet
Gastrointestinal side effects have included nausea, vomiting, diarrhea, glossitis, and atrophic glossitis, particularly with high doses. Gastrointestinal intolerance may be minimized by administering pyrimethamine (the active ingredient contained in Daraprim) with food.
Hypersensitivity reactions have been reported when pyrimethamine (the active ingredient contained in Daraprim) is administered with a sulfonamide. These reactions may be severe and include erythema multiforme, Stevens-Johnson Syndrome, toxic epidermal necrolysis, Lyell's syndrome, hepatitis, anaphylaxis, and pulmonary reactions. Fatal reactions have been estimated to occur in one of 11,000 to 25,000 patients treated. Hypersensitivity reactions have also been reported with pyrimethamine/clindamycin combinations and are usually limited to maculopapular rashes.
Hematologic side effects have occurred, especially when large doses of pyrimethamine (the active ingredient contained in Daraprim) are administered. Thrombocytopenia, megaloblastic anemia, leukopenia, pancytopenia, agranulocytosis, and fatalities have been reported.
Nervous system toxicity is problematic with higher dosages of pyrimethamine (the active ingredient contained in Daraprim) Ataxia, tremors, and seizures may occur.
Respiratory side effects have rarely included pulmonary eosinophilia.
Cardiovascular side effects have included arrhythmias, particularly with high doses.
Metabolic side effects have included hyperphenylalaninemia, particularly when pyrimethamine (the active ingredient contained in Daraprim) is given in combination with a sulfonamide.
Oncologic side effects have included two reports of malignancy; both were associated with pyrimethamine (the active ingredient contained in Daraprim) treatment for toxoplasmosis: 1 patient developed chronic granulocytic leukemia after 2 years of therapy and 1 patient developed reticulum cell sarcoma after 14 months of therapy. Animal studies have revealed increased lung tumors with intraperitoneal administration.
More Daraprim resources
- Daraprim Prescribing Information (FDA)
- Daraprim Concise Consumer Information (Cerner Multum)
- Daraprim Monograph (AHFS DI)
- Daraprim MedFacts Consumer Leaflet (Wolters Kluwer)
- Daraprim Advanced Consumer (Micromedex) - Includes Dosage Information
- Pyrimethamine Professional Patient Advice (Wolters Kluwer)
Disclaimer: Every effort has been made to ensure that the information provided is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This information does not endorse drugs, diagnose patients, or recommend therapy. This drug information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective, or appropriate for any given patient. Drugs.com does not assume any responsibility for any aspect of healthcare administered with the aid of information provided. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.